Nektar Therapeutics

NKTR
Real-time BATS EXCHANGE - 02/20 08:34:55 am
42.78USD
-0.07%
Prev.41.6900
Open42.1000
High43.1700
Low41.7597
Volume1 778 352
Financials
Sales 2018 1 198 M
EBIT 2018 693 M
R. net 2018 684 M
Tréso. 2018 979 M
Rend. 2018 -
P/E ratio 2018 11,04
P/E ratio 2019
EV / Sales 2018 5,37x
EV / Sales 2019 31,0x
Capitalization 7 410 M
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (68.6%);
- royalties (20.8%);
- product sales...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2019-05-06 Earnings Release
Trading Rating :
Investor Rating :
Latest news
02/18ROBBINS ARROYO LLP : Nektar Therapeutics (NKTR) Officials Harmed the Company According to Shareholder Lawsuit
BU
02/15NEKTAR THERAPEUTICS : Other Events (form 8-K)
AQ
02/15NEKTAR THERAPEUTICS : Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium
PU
02/06NEKTAR THERAPEUTICS : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
RE
01/17STRAP YOURSELF IN : Netflix is about to report
RE
01/11SEATTLE GENETICS : UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop
AQ
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Market Mover
DJ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishBearish
Resistance46,546,559,0
Spread/Res.-7,9%-7,9%-27%
Spread/Supp.4,4%41%40%
Support41,030,430,6